| HERMANS, C., P. L. F. GIANGRANDE, B. O MAHONY, P. DE KLEIJN, M. BEDFORD, A. BATOROVA, Jan BLATNÝ a K. JANSONE. European principles of inhibitor management in patients with haemophilia: implications of new treatment options. Orphanet Journal of Rare Diseases. London: England, 2020, roč. 15, č. 1, s. 1-4. ISSN 1750-1172. Dostupné z: https://dx.doi.org/10.1186/s13023-020-01511-8. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1681836,
author = {Hermans, C. and Giangrande, P. L. F. and O Mahony, B. and de Kleijn, P. and Bedford, M. and Batorova, A. and Blatný, Jan and Jansone, K.},
article_location = {London},
article_number = {1},
doi = {http://dx.doi.org/10.1186/s13023-020-01511-8},
keywords = {Haemophilia; Guidelines; Inhibitors; Factor VIII; Factor IX; Bypassing agents; Emicizumab; Immune tolerance},
language = {eng},
issn = {1750-1172},
journal = {Orphanet Journal of Rare Diseases},
title = {European principles of inhibitor management in patients with haemophilia: implications of new treatment options},
url = {https://ojrd.biomedcentral.com/track/pdf/10.1186/s13023-020-01511-8},
volume = {15},
year = {2020}
}
TY - JOUR
ID - 1681836
AU - Hermans, C. - Giangrande, P. L. F. - O Mahony, B. - de Kleijn, P. - Bedford, M. - Batorova, A. - Blatný, Jan - Jansone, K.
PY - 2020
TI - European principles of inhibitor management in patients with haemophilia: implications of new treatment options
JF - Orphanet Journal of Rare Diseases
VL - 15
IS - 1
SP - 1-4
EP - 1-4
PB - England
SN - 17501172
KW - Haemophilia
KW - Guidelines
KW - Inhibitors
KW - Factor VIII
KW - Factor IX
KW - Bypassing agents
KW - Emicizumab
KW - Immune tolerance
UR - https://ojrd.biomedcentral.com/track/pdf/10.1186/s13023-020-01511-8
L2 - https://ojrd.biomedcentral.com/track/pdf/10.1186/s13023-020-01511-8
N2 - In light of the rapidly changing landscape of haemophilia treatment, the authors of the position paper on the “European Principles of Inhibitor Management” published in 2018 (Table 1) now provide an update on the major impact of novel therapies that bypass and/or substitute clotting factor VIII (FVIII) and IX (FIX) in the care of haemophilia patients with FVIII- or FIXneutralizing allo-inhibitory antibodies (inhibitors).
ER -
HERMANS, C., P. L. F. GIANGRANDE, B. O MAHONY, P. DE KLEIJN, M. BEDFORD, A. BATOROVA, Jan BLATNÝ a K. JANSONE. European principles of inhibitor management in patients with haemophilia: implications of new treatment options. \textit{Orphanet Journal of Rare Diseases}. London: England, 2020, roč.~15, č.~1, s.~1-4. ISSN~1750-1172. Dostupné z: https://dx.doi.org/10.1186/s13023-020-01511-8.
|
